This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Development of a Fetal Sex Assay From Maternal Whole Blood

This study has been completed.
Information provided by:
Sequenom, Inc. Identifier:
First received: August 31, 2009
Last updated: January 31, 2011
Last verified: October 2009
Whole blood from pregnant women will be collected to develop a noninvasive fetal sex test.

Fetal Sex Determination

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Development of a Noninvasive Fetal Sex Determination Test Between 6 and 16 Weeks of Gestation

Further study details as provided by Sequenom, Inc.:

Biospecimen Retention:   Samples With DNA
Plasma and PBMCs

Estimated Enrollment: 500
Study Start Date: June 2008
Study Completion Date: July 2010
Primary Completion Date: July 2010 (Final data collection date for primary outcome measure)
Pregnant females
Women who are pregnant and between 6 and 16 weeks of gestation and who are 18 to 64 years of age.

Detailed Description:
This is an observational study whereby samples will be tested to determine the presence or absence of fetal Y chromosome genes to test for the fetal sex of the baby. The blood draw will occur between 6 to 16 weeks of gestation. The fetal gender will be requested at or soon after delivery if fetal sex was not previously obtained by CVS or amniocentesis genetic analysis.

Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Pregnant women between 6 and 16 weeks of gestation.

Inclusion Criteria:

  • Subject is 18-64 years of age
  • Subject is female
  • Subject is pregnant and between 6 and 16 weeks of gestation
  • Subject provides a signed and dated informed consent
  • If subject undergoes a routine ultrasound between weeks 16 and 28, she agrees to provide the fetal sex results
  • If subject undergoes an invasive procedure, she agrees to provide the fetal sex results

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00970047

United States, California
NCOG Medical Group
San Diego, California, United States, 92037
San Diego, California, United States, 92121
Scripps Clinic Medial Group
San Diego, California, United States, 92128
Sponsors and Collaborators
Sequenom, Inc.
Study Director: Allan Bombard, MD, MBA Sequenom, Inc.
  More Information

Responsible Party: Allan Bombard / Chief Medical Officer, Sequenom, Inc. Identifier: NCT00970047     History of Changes
Other Study ID Numbers: SQNM-FS-101
Study First Received: August 31, 2009
Last Updated: January 31, 2011

Keywords provided by Sequenom, Inc.:
fetal sex determination
gender determination
noninvasive test
fetal DNA processed this record on August 16, 2017